midodrine + albumin

Midodrine and albumin is a combination therapy primarily used in the management of hepatorenal syndrome (HRS) and other complications of liver disease. This combination has shown significant benefits in improving renal function and survival rates in patients with cirrhosis. ## Therapeutic Applications The midodrine and albumin combination is used in several clinical scenarios: **Hepatorenal Syndrome (HRS)** The combination of midodrine, albumin, and often octreotide has shown significant improvement in short-term survival and renal function in both HRS type 1 and type 2 patients. In a study comparing patients who received this therapy versus those who didn't, the treatment group showed markedly better transplant-free survival (median 101 days vs. 18 days)[1]. This combination serves as an effective bridge to liver transplantation in HRS type 1 and may prevent progression of HRS type 2 to the more severe type 1[1]. **Paracentesis-Induced Circulatory Dysfunction (PICD)** When large volumes of ascitic fluid are removed during paracentesis, patients can develop circulatory dysfunction. Midodrine and albumin therapy has been investigated for preventing this complication, with mixed results. Some studies suggest that midodrine alone may not be as effective as albumin in preventing PICD, while others indicate that when midodrine dosage is properly titrated to maintain adequate blood pressure, it can be as effective as intravenous albumin[6]. **Refractory Ascites** The combination has shown promise in managing refractory ascites in cirrhotic patients. A study investigating a one-month course of therapy with midodrine, octreotide-LAR, and albumin observed a significant reduction in plasma renin and aldosterone concentration and a trend toward reduced volume of ascitic fluid requiring paracentesis[6]. ## Mechanism of Action The therapeutic effect of this combination stems from their complementary mechanisms: **Midodrine** is an orally available α1-adrenergic agonist that functions as a vasoconstrictor. It increases effective circulating blood volume and renal perfusion by raising systemic and splanchnic blood pressure[6]. Midodrine is actually a prodrug that is metabolized by the liver into its active form, desglymidodrine[6]. **Albumin** helps maintain plasma oncotic pressure and has important binding and transport functions. In the context of liver disease, albumin administration helps expand plasma volume, improve cardiac output, and counteract the vasodilatory state typical of advanced cirrhosis[5]. Together, these agents work to improve circulatory function and renal perfusion in patients with decompensated cirrhosis, potentially reversing the pathophysiological mechanisms that lead to complications like HRS and refractory ascites. ## Dosing Considerations When used for HRS, midodrine is typically administered at doses ranging from 5-10 mg every 8 hours, often titrated to maintain mean arterial pressure 10 mmHg above baseline[6]. Albumin dosing varies by indication but is generally administered intravenously. This combination therapy represents an important treatment option for patients with advanced liver disease, particularly when other interventions are limited or as a bridge to definitive treatments like liver transplantation.

Brand names

ProAmatineOrvatenGutronAlbuteinFlexbuminAlbukedAlbuminar

Other names

Midodrine hydrochlorideHuman serum albuminHSA